WHWK

Whitehawk Therapeutics, Inc.

$3.08

-4.35%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Source: Yahoo Finance
AI summary

Price & performance

1M-12.5%
3M-32.3%
YTD+26.2%
1Y+41.3%
52-week range—
Beta1.22
Full chart and returns against a benchmark

Q-Score

49/ 100

Quality against peers; 50 is the peer median.

Growth52
Risk52
Performance48
Valuation50
Profitability48
Leverage53
Sentiment69
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$7.1M-72.5%
Net income-$20.6M
Net margin-288.3%-43.1 pts
Historical fundamentals

Revenue exposure

0%of revenue from outside the US
United States100%
Largest customer60%
Regions, segments, customers and suppliers

Valuation

WHWKIndustryP/E—89.69P/S—11.88EV/EBITDA—67.10P/B1.086.22PEG—4.02
Dividend yield0.00%
Every valuation metric

Earnings

Nov 9next report
EPS estimate$-0.24
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate